Immune-mediated hemolytic anemia (IMHA) is a serious blood disorder that causes the body to destroy its own red blood cells. Previously funded work identified a safe and promising drug to treat IMHA in dogs. In this study, researchers will further investigate the efficacy of this drug in a clinical trial of client-owned dogs with IMHA. If successful, this would be a major step toward a new drug to treat this deadly disease.
Grant amount awarded
Robert Goggs, BVSc, PhD